Inozyme Pharma Inc. (INZY) News
Filter INZY News Items
INZY News Results
|Loading, please wait...|
INZY News Highlights
- For INZY, its 30 day story count is now at 2.
- Over the past 20 days, the trend for INZY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- MSC are the most mentioned tickers in articles about INZY.
Latest INZY News From Around the Web
Below are the latest news stories about INOZYME PHARMA INC that investors may wish to consider to help them evaluate INZY as an investment opportunity.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference. The prerecorded presentation will become available on-demand on Monday, September 12, 2022, at 7:00 AM ET. A replay of
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.
bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.
Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.
Needham analyst Joseph Stringer reiterated a Buy rating on Inozyme Pharma (INZY - Research Report) today and set a price target of $23.00. The company's shares opened today at $3.41.Stringer covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Alnylam Pharma, and Lexicon Pharmaceuticals. According to TipRanks, Stringer has an average return of 5.3% and a 46.63% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inozyme Pharma with a $22.00 average price target, representing a 545.16% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $20.
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Inozyme Pharma (INZY - Research Report), with a price target of $20.00. The company's shares opened today at $3.41.White covers the Healthcare sector, focusing on stocks such as Clovis Oncology, G1 Therapeutics, and ChemoCentryx. According to TipRanks, White has an average return of -14.7% and a 32.96% success rate on recommended stocks. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $22.00, a 545.16% upside from current levels. In a report released today, Needham also reiterated a Buy rating on the stock with a $23.00 price target.
- Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency – - Appointed Kurt Gunter, M.D. as senior vice president and chief medical officer - - Secured flexible debt facility for up to $70 million - - Cash, cash equivalents and investments as of quarter end, together with first tranche of debt facility, funds cash flow requirements into the second quarter of 2024 – BOSTON, Aug. 15, 2022 (GLOBE NE
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline